Abstract
HupA is a potent, reversible and selective inhibitor of AChE with a rapid absorption and penetration into the brain in animal tests. It exhibits memory-enhancing activities in animal and clinical trials. Compared to tacrine and donepezil, HupA possesses a longer duration of action and higher therapeutic index, and the peripheral cholinergic side effects are minimal at therapeutic doses. This review article deals with a comprehensive survey of the progress in chemical and pharmacological studies of HupA including the isolation and structure elucidation, pharmacological actions, total synthesis, SAR studies and the future development of HupA. Recently, it has been reported that HupA could reduce neuronal cell death caused by glutamate. The dual bio-activities of HupA would further enhance its value and potentiality as the therapeutic agent for Alzheimers disease.
Keywords: huperzine A, inhibitor of AChE, revesibile inhibitors if AChE, lycopoduim, HupA, Huperzia serrata, alzheimer s disease, glutamate, dual bio activities, neuronal cell death, structure elucidation, pharmacological actions, total synthesis, SAR studies, donepezil, brain receptor, learning, memory, cyvlohexanedione mono ethylene ketal 10, keto ester, pyridine derivatives, dimethyl 4 oxopimelate, recemic HupA, stereiselective michael aldok reaction, diastereomeric separation, chiral catalyst, natura HupA, enantioselective palladium catalyzed bicycloannulation, structure activity relationships, the anti AChE activities, zusammen together, entgegen, lithium aluminium hydride, enantiomer excess, tetramethylguanidine, rectus, sinister left
Current Medicinal Chemistry
Title: Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimers Disease
Volume: 7 Issue: 3
Author(s): D. L. Bai, X. C. Tang and X. C. He
Affiliation:
Keywords: huperzine A, inhibitor of AChE, revesibile inhibitors if AChE, lycopoduim, HupA, Huperzia serrata, alzheimer s disease, glutamate, dual bio activities, neuronal cell death, structure elucidation, pharmacological actions, total synthesis, SAR studies, donepezil, brain receptor, learning, memory, cyvlohexanedione mono ethylene ketal 10, keto ester, pyridine derivatives, dimethyl 4 oxopimelate, recemic HupA, stereiselective michael aldok reaction, diastereomeric separation, chiral catalyst, natura HupA, enantioselective palladium catalyzed bicycloannulation, structure activity relationships, the anti AChE activities, zusammen together, entgegen, lithium aluminium hydride, enantiomer excess, tetramethylguanidine, rectus, sinister left
Abstract: HupA is a potent, reversible and selective inhibitor of AChE with a rapid absorption and penetration into the brain in animal tests. It exhibits memory-enhancing activities in animal and clinical trials. Compared to tacrine and donepezil, HupA possesses a longer duration of action and higher therapeutic index, and the peripheral cholinergic side effects are minimal at therapeutic doses. This review article deals with a comprehensive survey of the progress in chemical and pharmacological studies of HupA including the isolation and structure elucidation, pharmacological actions, total synthesis, SAR studies and the future development of HupA. Recently, it has been reported that HupA could reduce neuronal cell death caused by glutamate. The dual bio-activities of HupA would further enhance its value and potentiality as the therapeutic agent for Alzheimers disease.
Export Options
About this article
Cite this article as:
Bai L. D., Tang C. X. and He C. X., Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimers Disease, Current Medicinal Chemistry 2000; 7 (3) . https://dx.doi.org/10.2174/0929867003375281
DOI https://dx.doi.org/10.2174/0929867003375281 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
4D-QSAR Model for Compounds with Binding Affinity Towards Dopamine D<sub>2</sub> Receptors
Letters in Drug Design & Discovery The Function of the Selective Inhibitors of Cycloxygenase 2
Mini-Reviews in Medicinal Chemistry Atypical Antipsychotics: Pharmacokinetics, Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Differences in Post-ischemic Motor Recovery and Angiogenesis of MCAO Rats Following Electroacupuncture at Different Acupoints
Current Neurovascular Research Inhibition of microRNA-155 Alleviates Cognitive Impairment in Alzheimer’s Disease and Involvement of Neuroinflammation
Current Alzheimer Research An Optimal Approach for Selecting Discriminant Regions for the Diagnosis of Alzheimer's Disease
Current Alzheimer Research Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy
Current Medicinal Chemistry Development of Novel Amyloid Imaging Agents Based Upon Thioflavin S
Current Alzheimer Research The Mediterranean and other Dietary Patterns in Secondary Cardiovascular Disease Prevention: A Review
Current Vascular Pharmacology Is Dopamine Neurotransmission Altered in Prodromal Schizophrenia? A Review of the Evidence
Current Pharmaceutical Design Subject Index To Volume 7
Current Drug Metabolism Quality of Life in People with Coeliac Disease: Psychological and Socio- Economic Aspects
Endocrine, Metabolic & Immune Disorders - Drug Targets Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase
Letters in Drug Design & Discovery Editorial (Thematic Issue: Denham Harman - Pioneer of the Free Radical Theory of Aging)
Current Aging Science Classical Neurotransmitters and Neuropeptides Involved in Schizophrenia: How to Choose the Appropriate Antipsychotic Drug?
Current Drug Therapy Mechanisms Involved in the Protective Effects of Metformin Against Nonalcoholic Fatty Liver Disease
Current Medicinal Chemistry Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Neuropharmacology Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design